SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 2/20/18 Shire plc 10-K 12/31/17 168:31M |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 2.74M 2: EX-10.22 Material Contract HTML 58K 3: EX-10.23 Material Contract HTML 54K 4: EX-10.24 Material Contract HTML 120K 5: EX-21 Subsidiaries List HTML 88K 6: EX-23.1 Consent of Experts or Counsel HTML 44K 7: EX-23.2 Consent of Experts or Counsel HTML 44K 8: EX-31.1 Certification -- §302 - SOA'02 HTML 50K 9: EX-31.2 Certification -- §302 - SOA'02 HTML 49K 10: EX-32.1 Certification -- §906 - SOA'02 HTML 45K 17: R1 Document and Entity Information HTML 72K 18: R2 Consolidated Balance Sheets HTML 132K 19: R3 Consolidated Balance Sheets (Parenthetical) HTML 54K 20: R4 Consolidated Statements of Operations HTML 143K 21: R5 Consolidated Statements of Comprehensive Income HTML 85K 22: R6 Consolidated Statements of Comprehensive Income HTML 52K (Parenthetical) 23: R7 Consolidated Statement of Changes in Equity HTML 111K 24: R8 Consolidated Statement of Changes in Equity HTML 52K (Parenthetical) 25: R9 Consolidated Statements of Cash Flows HTML 144K 26: R10 Description of Operations HTML 47K 27: R11 Summary of Significant Accounting Policies HTML 168K 28: R12 Business Combinations HTML 181K 29: R13 Collaborative and Other Licensing Arrangements HTML 62K 30: R14 Integration and Acquisition Costs HTML 71K 31: R15 Reorganization Costs HTML 49K 32: R16 Results of Discontinued Operations HTML 51K 33: R17 Accounts Receivable, Net HTML 61K 34: R18 Inventories HTML 53K 35: R19 Prepaid Expenses and Other Current Assets HTML 55K 36: R20 Property, Plant and Equipment, Net HTML 61K 37: R21 Intangible Assets HTML 94K 38: R22 Goodwill HTML 53K 39: R23 Fair Value Measurement HTML 179K 40: R24 Financial Instruments HTML 141K 41: R25 Accounts Payable and Accrued Expenses HTML 56K 42: R26 Borrowings and Capital Leases HTML 128K 43: R27 Other Current Liabilities HTML 55K 44: R28 Retirement and Other Benefit Programs HTML 531K 45: R29 Accumulated Other Comprehensive Income/(Loss) HTML 130K 46: R30 Taxation HTML 226K 47: R31 Earnings Per Share HTML 90K 48: R32 Share-based Compensation Plans HTML 181K 49: R33 Commitments and Contingencies HTML 65K 50: R34 Legal and Other Proceedings HTML 67K 51: R35 Shareholders' Equity HTML 58K 52: R36 Segment Reporting HTML 158K 53: R37 Agreements and Transactions HTML 55K 54: R38 Subsequent Events HTML 47K 55: R39 Guarantor Financial Information HTML 1.06M 56: R40 Quarterly Results of Operations (Unaudited) HTML 124K 57: R41 Schedule II - Valuation and Qualifying Accounts HTML 106K 58: R42 Notes to the New Shire Income Access Share Trust HTML 57K Financial Statements 59: R43 Summary of Significant Accounting Policies HTML 257K (Policies) 60: R44 Summary of Significant Accounting Policies HTML 61K (Tables) 61: R45 Business Combinations (Tables) HTML 150K 62: R46 Integration and Acquisition Costs (Tables) HTML 64K 63: R47 Accounts Receivable, Net (Tables) HTML 55K 64: R48 Inventories (Tables) HTML 53K 65: R49 Prepaid Expenses and Other Current Assets (Tables) HTML 55K 66: R50 Property, Plant and Equipment, Net (Tables) HTML 61K 67: R51 Intangible Assets (Tables) HTML 94K 68: R52 Goodwill (Tables) HTML 52K 69: R53 Fair Value Measurement (Tables) HTML 174K 70: R54 Financial Instruments (Tables) HTML 134K 71: R55 Accounts Payable and Accrued Expenses (Tables) HTML 56K 72: R56 Borrowings and Capital Leases (Tables) HTML 118K 73: R57 Other Current Liabilities (Tables) HTML 54K 74: R58 Retirement and Other Benefit Programs (Tables) HTML 519K 75: R59 Accumulated Other Comprehensive Income/(Loss) HTML 129K (Tables) 76: R60 Taxation Taxation (Tables) HTML 221K 77: R61 Earnings Per Share (Tables) HTML 91K 78: R62 Share-based Compensation Plans (Tables) HTML 158K 79: R63 Commitments and Contingencies (Tables) HTML 51K 80: R64 Segment Reporting (Tables) HTML 164K 81: R65 Guarantor Financial Information (Tables) HTML 947K 82: R66 Quarterly Results of Operations (Unaudited) HTML 124K (Tables) 83: R67 Summary of Significant Accounting Policies HTML 79K (Narrative) (Details) 84: R68 Summary of Significant Accounting Policies (Useful HTML 55K Lives of Property, Plant and Equipment) (Details) 85: R69 Business Combinations (Acquisition of Baxalta) HTML 117K (Narrative) (Details) 86: R70 Business Combinations (Baxalta Purchase Price HTML 57K Consideration) (Details) 87: R71 Business Combinations (Baxalta Assets Acquired and HTML 136K Liabilities Assumed) (Details) 88: R72 Business Combinations (Baxalta Pro Forma HTML 62K Information) (Details) 89: R73 Business Combinations (Acquisition of Dyax) HTML 107K (Narrative) (Details) 90: R74 Business Combinations (Dyax Assets Acquired and HTML 102K Liabilities Assumed) (Details) 91: R75 Business Combinations (Dyax Pro Forma Information) HTML 58K (Details) 92: R76 Collaborative and Other Licensing Arrangements HTML 65K (Narrative) (Details) 93: R77 Integration and Acquisition Costs (Narrative) HTML 76K (Details) 94: R78 Integration and Acquisition Costs (Summary of HTML 56K Employee Termination Related Reserve and Other) (Details) 95: R79 Reorganization Costs (Narrative) (Details) HTML 51K 96: R80 Results of Discontinued Operations (Narrative) HTML 70K (Details) 97: R81 Accounts Receivable, Net (Narrative) (Details) HTML 50K 98: R82 Accounts Receivable, Net (Summary of Reserve for HTML 53K Discounts and Allowances) (Details) 99: R83 Inventories (Summary of Inventories) (Details) HTML 54K 100: R84 Prepaid Expenses and Other Current Assets HTML 56K (Details) 101: R85 Property, Plant and Equipment, Net (Summary of HTML 61K Property, Plant and Equipment) (Details) 102: R86 Property, Plant and Equipment, Net (Narrative) HTML 62K (Details) 103: R87 Intangible Assets (Summary of Intangible Assets) HTML 59K (Details) 104: R88 Intangible Assets (Roll Forward) (Details) HTML 56K 105: R89 Intangible Assets (Narrative) (Details) HTML 60K 106: R90 Intangible Assets (Future Amortization Expense) HTML 54K (Details) 107: R91 Goodwill (Rollforward of Goodwill) (Details) HTML 51K 108: R92 Fair Value Measurement (Assets and Liabilities HTML 83K Measured on a Recurring Basis) (Details) 109: R93 Fair Value Measurement (Assets and Liabilities HTML 54K Measure at Fair Value on Recurring Basis using Level 3 Inputs) (Details) 110: R94 Fair Value Measurement (Qualitative Information HTML 76K About Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs) (Details) 111: R95 Fair Value Measurement (Financial Assets and HTML 61K Liabilities Not Measured on a Recurring Basis) (Details) 112: R96 Fair Value Measurement (Narrative) (Details) HTML 58K 113: R97 Financial Instruments (Summary of Derivative HTML 59K Instruments) (Details) 114: R98 Financial Instruments (Narrative) (Details) HTML 58K 115: R99 Financial Instruments (Derivative Income Statement HTML 65K Location, Gains & Losses) (Details) 116: R100 Financial Instruments (Foreign Exchange Risk and HTML 84K Its Classification on Balance Sheet) (Details) 117: R101 Accounts Payable and Accrued Expenses (Details) HTML 55K 118: R102 Borrowings and Capital Leases (Short-term HTML 61K Borrowings) (Details) 119: R103 Borrowings and Capital Leases (Long-term HTML 66K Borrowings) (Details) 120: R104 Borrowings and Capital Leases (Maturities) HTML 68K (Details) 121: R105 Borrowings and Capital Leases (Senior Notes Issued HTML 68K by SAIIDAC) (Details) 122: R106 Borrowings and Capital Leases (Senior Notes HTML 77K Related to Baxalta Acquisition) (Details) 123: R107 Borrowings and Capital Leases (Narrative) HTML 88K (Details) 124: R108 Other Current Liabilities (Details) HTML 54K 125: R109 Retirement and Other Benefit Programs (Change in HTML 138K Benefit Obligations and Fair Value of Plan Assets) (Details) 126: R110 Retirement and Other Benefit Programs (Narrative) HTML 83K (Details) 127: R111 Retirement and Other Benefit Programs (Summary of HTML 53K Funded Status of Plan) (Details) 128: R112 Retirement and Other Benefit Programs (Expected HTML 66K Net Pension and OPEB Plan Payments for the Next 10 Years) (Details) 129: R113 Retirement and Other Benefit Programs (Summary of HTML 62K Amounts Recorded in AOCI) (Details) 130: R114 Retirement and Other Benefit Programs (Summary of HTML 65K Net Periodic Benefit Cost) (Details) 131: R115 Retirement and Other Benefit Programs HTML 75K (Weighted-Average Assumptions Used for Benefit Obligation and Net Periodic Benefit Cost) (Details) 132: R116 Retirement and Other Benefit Programs (Fair Value HTML 146K Measurements of Plan Assets) (Details) 133: R117 Retirement and Other Benefit Programs (Funded and HTML 66K Unfunded Statuses of Plans) (Details) 134: R118 Accumulated Other Comprehensive Income/(Loss) HTML 76K (Summary of Changes in Accumulated Other Comprehensive Income/(Loss)) (Details) 135: R119 Accumulated Other Comprehensive Income/(Loss) HTML 90K (Reclassifications from Accumulated Other Comprehensive Income) (Details) 136: R120 Taxation (Narrative) (Details) HTML 86K 137: R121 Taxation (Components of Pre-tax Income) (Details) HTML 56K 138: R122 Taxation (Pretax Income from Continuing Operations HTML 79K and Provision for Income Taxes) (Details) 139: R123 Taxation (Effective Income Tax Rate HTML 124K Reconciliation, and Statutory Tax Rates) (Details) 140: R124 Taxation (Rollforward of Unrecognized Tax HTML 71K Benefits) (Details) 141: R125 Taxation (Deferred Tax Assets and Liabilities, and HTML 101K Valuation Allowances) (Details) 142: R126 Taxation (Operating Loss and Tax Credit HTML 72K Carryforwards, and Their Expiration Dates) (Details) 143: R127 Earnings Per Share (Calculation of EPS) (Details) HTML 100K 144: R128 Earnings Per Share (Summary of Antidilutive HTML 48K Securities) (Details) 145: R129 Share-based Compensation Plans (Share-based HTML 63K Compensation Expense) (Details) 146: R130 Share-based Compensation Plans (Narrative) HTML 174K (Details) 147: R131 Share-based Compensation Plans (Summary of Awards HTML 85K Outstanding and Vesting Schedules) (Details) 148: R132 Share-based Compensation Plans (Stock Options and HTML 107K SARs) (Details) 149: R133 Share-based Compensation Plans (Performance Share HTML 74K Awards) (Details) 150: R134 Share-based Compensation Plans (Fair Value HTML 62K Assumptions) (Details) 151: R135 Commitments and Contingencies (Future Minimum HTML 62K Lease Payments) (Details) 152: R136 Commitments and Contingencies (Narrative) HTML 63K (Details) 153: R137 Legal and Other Proceedings (Narrative) (Details) HTML 45K 154: R138 Shareholders' Equity (Narrative) (Details) HTML 69K 155: R139 Segment Reporting (Narrative) (Details) HTML 46K 156: R140 Segment Reporting (Revenues and Long-lived Assets HTML 64K by Geographic Location) (Details) 157: R141 Segment Reporting (Revenues and Accounts HTML 65K Receivable by Major Customers) (Details) 158: R142 Segment Reporting (Revenue by Product) (Details) HTML 132K 159: R143 Agreements and Transactions with Baxter HTML 68K (Narrative) (Detail) 160: R144 Guarantor Financial Information (Senior Notes) HTML 67K (Details) 161: R145 Guarantor Financial Information (Consolidating HTML 206K Balance Sheets) (Details) 162: R146 Guarantor Financial Information (Consolidating HTML 218K Statements of Income) (Details) 163: R147 Guarantor Financial Information (Condensed HTML 160K Consolidating Statement of Cash Flows) (Details) 164: R148 Schedule II - Valuation and Qualifying Accounts HTML 67K (Details) 165: R149 Quarterly Results of Operations (Unaudited) HTML 93K (Details) 167: XML IDEA XML File -- Filing Summary XML 308K 166: EXCEL IDEA Workbook of Financial Reports XLSX 236K 11: EX-101.INS XBRL Instance -- shpgf-20171231 XML 10.49M 13: EX-101.CAL XBRL Calculations -- shpgf-20171231_cal XML 470K 14: EX-101.DEF XBRL Definitions -- shpgf-20171231_def XML 2.08M 15: EX-101.LAB XBRL Labels -- shpgf-20171231_lab XML 3.49M 16: EX-101.PRE XBRL Presentations -- shpgf-20171231_pre XML 2.56M 12: EX-101.SCH XBRL Schema -- shpgf-20171231 XSD 363K 168: ZIP XBRL Zipped Folder -- 0000936402-18-000007-xbrl Zip 685K
Exhibit |
Name | Country |
Shire Albania Sh.p.k. | Albania |
Baxalta Argentina S.A.U. | Argentina |
Shire
Human Genetic Therapies S.A. | Argentina |
Baxalta Australia Pty. Ltd. | Australia |
Farboud Pty Ltd | Australia |
Fibrotech Therapeutics Pty Ltd | Australia |
Shire Australia Pty Limited | Australia |
Viropharma Pty Ltd | Australia |
Baxalta
Innovations GmbH | Austria |
Baxter AG | Austria |
Shire Austria GmbH | Austria |
Shire Intellectual Property 2 SRL | Barbados |
Shire Intellectual Property SRL | Barbados |
Baxalta Belgium Manufacturing S.A. | Belgium |
Baxalta
Belgium SPRL | Belgium |
Baxalta Services Europe SPRL | Belgium |
Shire Belgium BVBA | Belgium |
Shire Services BVBA | Belgium |
Shire Holdings Limited | Bermuda |
Viropharma Holdings Limited | Bermuda |
Shire
Farmacêutica Brasil Ltda | Brazil |
Baxalta Bulgaria EOOD | Bulgaria |
Shire Bulgaria EOOD | Bulgaria |
Baxalta Canada Corporation | Canada |
NPS Holdings Company | Canada |
NPS Pharma Canada Inc. | Canada |
Shire
IP Services Corporation | Canada |
Shire Pharma Canada ULC | Canada |
Shire 2005 Investments Limited | Cayman Islands |
Shire Finance Limited | Cayman Islands |
Shire Chile SpA | Chile |
Shire BioScience (Shanghai) Co. Ltd. | China |
Shire
Hong Kong Limited | China |
Shire (Shanghai) Pharmaceuticals Consultancy Co., Ltd. | China |
Baxalta Colombia S.A.S. | Colombia |
Shire Biotech Costa Rica, S.R.L. | Costa Rica |
Shire društvo s ogranièenom odgovornošæu za trgovinu i usluge | Croatia |
SG Biotech Limited***** | Cyprus |
Shire
Czech s.r.o. | Czech Republic |
Shire Denmark A/S | Denmark |
Shire Biotech Denmark ApS | Denmark |
Baxalta-Ecuador S.A. | Ecuador |
Baxalta Estonia OU | Republic of Estonia |
Shire Finland Oy | Finland |
Shire
Biotech Finland Oy | Finland |
Shire France S.A.S | France |
Baxalta Deutschland GmbH | Germany |
Jerini Ophthalmic Holding GmbH | Germany |
Shire
Central & Eastern Europe GmbH | Germany |
Shire Deutschland GmbH | Germany |
Shire Deutschland Investments GmbH | Germany |
Shire Orphan Therapies GmbH | Germany |
SuppreMol GmbH | Germany |
Baxalta BioScience Greece Single Member LLC | Greece |
Shire
Hellas Pharmaceuticals Import Export and Marketing S.A. | Greece |
Shire Guatemala, Sociedad Anónima | Guatemala |
Baxalta Hungary Limited Liability Company | Hungary |
Shire Hungary Kft | Hungary |
Baxalta BioScience India Private Limited | India |
Shire Biotech India Private Limited | India |
Baxalta
Ireland Financing Limited | Ireland |
Navillus Insurance Company Designated Activity Company | Ireland |
NPS Pharma Holdings Limited | Ireland |
NPS Pharma International Limited | Ireland |
Pharma International Insurance Designated Activity Company | Ireland |
Shire Acquisitions Investments Ireland Designated Activity Company | Ireland |
Shire
Biopharmaceuticals Ireland Limited | Ireland |
Shire Holdings Ireland Unlimited Company | Ireland |
Shire Holdings Ireland No.2 Limited | Ireland |
Shire Holdings Ireland No.3 Limited | Ireland |
Shire Intellectual Property Ireland Limited | Ireland |
Shire Ireland Finance Limited | Ireland |
Shire
Ireland Finance Trading Limited | Ireland |
Shire Ireland Investment Limited | Ireland |
Shire Ireland Plasma Limited | Ireland |
Shire Ireland Premacure Investment Unlimited Company | Ireland |
Shire Pharmaceutical Holdings Ireland Limited* | Ireland |
Shire Pharmaceutical Investment Trading Ireland Unlimited Company | Ireland |
Shire
Pharmaceutical Investments 2008 Unlimited Company | Ireland |
Shire Pharmaceutical Services Ireland Limited | Ireland |
Shire Pharmaceuticals Finance Ireland Unlimited Company | Ireland |
Shire Pharmaceuticals International Unlimited Company | Ireland |
Shire Pharmaceuticals Investments 2007 Unlimited Company | Ireland |
Shire
Pharmaceuticals Ireland Limited | Ireland |
Shire Pharmaceutical Israel Ltd | Israel |
Baxalta Italy Holding S.r.l. | Italy |
Baxalta Italy S.r.l. | Italy |
Baxter Manufacturing S.p.A. | Italy |
Shire Italia S.p.A. | Italy |
Baxalta
Japan Limited | Japan |
Shire Japan KK | Japan |
Shire Biopharmaceuticals Holdings Ireland Limited | Jersey |
Shire Jersey Limited | Jersey |
Baxalta Kazakhstan LLP | Republic of Kazakhstan |
Shire Pharma Korea Yuhan Hoesa | Republic of Korea |
Baxalta
Lithuania UAB | Lithuania |
Shire Holdings Europe No.2 S.à r.l. | Luxembourg |
Shire Holdings Luxembourg S.à r.l. | Luxembourg |
Shire Luxembourg Finance S.à r.l. | Luxembourg |
Shire
Luxembourg Intellectual Property No.2 S.à r.l. | Luxembourg |
Shire Luxembourg Intellectual Property S.à r.l. | Luxembourg |
Shire Luxembourg S.à r.l. | Luxembourg |
Shire Pharmaceuticals International Finance S.à r.l. | Luxembourg |
Shire Sweden Holdings S.à r.l. | Luxembourg |
Baxalta Malaysia SDN. BHD. | Malaysia |
Shire
Pharmaceuticals Mexico S.A. de C.V. | Mexico |
Baxalta Holding B.V. | Netherlands |
Baxalta Investments B.V. | Netherlands |
Baxalta Netherlands B.V. | Netherlands |
Baxalta Netherlands Holding B.V. | Netherlands |
Baxalta Netherlands Investment B.V. | Netherlands |
Shire
Holdings Europe B.V. | Netherlands |
Shire International Licensing BV | Netherlands |
Shire Licensing V.O.F. | Netherlands |
Tanaud International BV | Netherlands |
Baxalta New Zealand Limited | New Zealand |
Shire New Zealand Limited | New Zealand |
Shire
Norway AS | Norway |
Shire Biotech Norway AS | Norway |
Shire Panama, S.A. | Panama |
Shire Peru S.A.C. | Peru |
Shire Polska Sp. z o. o. | Poland |
Shire Pharmaceuticals Portugal, Lda | Portugal |
Baxalta
S.R.L. | Romania |
Shire Romania SRL | Romania |
SG Biotech Joint Stock Company******* | Russian Federation |
Shire Biotech Rus Limited Liability Company | Russian Federation |
Shire Rus Limited Liability Company | Russian Federation |
Shire doo Beograd | Serbia |
Shire
Singapore Pte. Ltd. | Singapore |
Baxalta Slovakia s.r.o. | Slovak Republic |
Shire Slovakia s.r.o. | Slovak Republic |
Baxalta Biofarmacevtska druzba d.o.o | Slovenia |
Shire Pharmaceuticals South Africa (Pty) Ltd | South Africa |
Shire Pharmaceuticals Iberica S.L.U. | Spain |
DuoCort
Pharma AB | Sweden |
Premacure AB | Sweden |
Premacure Uppsala AB | Sweden |
Shire Human Genetic Therapies AB | Sweden |
Shire Sweden AB | Sweden |
ViroPharma AB | Sweden |
SG Biotech Sàrl*** | Switzerland |
Shire
Export Services GmbH | Switzerland |
Baxalta GmbH | Switzerland |
Baxalta Manufacturing S.à r.l. | Switzerland |
Baxalta Recombinant S.à r.l. | Switzerland |
Baxalta Schweiz AG | Switzerland |
Shire International Finance GmbH | Switzerland |
Shire
International GmbH | Switzerland |
Shire Switzerland GmbH | Switzerland |
Shire Biotech Taiwan Limited | Taiwan |
Taiwan Shire Limited Company | Taiwan |
Shire (Thailand) Limited | Thailand |
Baxalta Tunisia SARL | Tunisia |
Eczacýbaþý
Shire Saðlýk Ürünleri Sanayi ve Ticaret A.Þ.**** | Turkey |
Shire Ilac Ticaret Limited Sirketi | Turkey |
Baxalta Ukraine LLC | Ukraine |
Shire Ukraine LLC | Ukraine |
Auralis Limited | United Kingdom |
Baxalta UK Holdco Limited | United Kingdom |
Baxalta
UK Investments Ltd. | United Kingdom |
Baxalta UK Limited | United Kingdom |
Dyax Limited | United Kingdom |
Lumena Pharma UK Limited | United Kingdom |
Monmouth Pharmaceuticals Limited | United Kingdom |
NPS Pharma UK Limited | United Kingdom |
Rybar
Laboratories Limited | United Kingdom |
Shire Biopharmaceuticals Holdings | United Kingdom |
Shire Biotech UK Holdings Limited | United Kingdom |
Shire Corporate Services Limited | United Kingdom |
Shire Europe Finance | United Kingdom |
Shire Europe Limited | United
Kingdom |
Shire Global Finance | United Kingdom |
Shire Holdings Europe Limited | United Kingdom |
Shire Holdings UK Canada Limited | United Kingdom |
Shire Holdings UK Limited | United Kingdom |
Shire Human Genetic Therapies Limited | United Kingdom |
Shire
Human Genetic Therapies UK Limited | United Kingdom |
Shire Investments & Finance (U.K.) Company | United Kingdom |
Shire Pharmaceutical Contracts Limited | United Kingdom |
Shire Pharmaceutical Development Limited | United Kingdom |
Shire Pharmaceuticals Group | United Kingdom |
Shire
Pharmaceuticals Limited | United Kingdom |
Shire Pharmaceuticals Services Limited | United Kingdom |
Shire UK Investments Limited | United Kingdom |
Shire US Investments | United Kingdom |
Sigma-Tau Pharma Limited | United Kingdom |
Sparkleflame Limited | United Kingdom |
The
Endocrine Centre Limited | United Kingdom |
Viropharma Limited | United Kingdom |
AesRX, LLC | United States |
Amsterdam Newco, Inc | United States |
Armagen Technologies, Inc****** | United States |
Baxalta Export Corporation | United States |
Baxalta
Holdings LLC | United States |
Baxalta Incorporated | United States |
Baxalta Mexico Holding LLC | United States |
Baxalta Singapore Holding LLC | United States |
Baxalta
US Inc. | United States |
Baxalta World Trade LLC | United States |
Baxalta Worldwide LLC | United States |
BearTracks, Inc. | United States |
Bikam Pharmaceuticals, Inc. | United States |
BioLife Plasma LLC | United States |
BioLife
Plasma Services LP | United States |
Cinacalcet Royalty Sub LLC | United States |
Dyax Corp. | United States |
FerroKin BioSciences, Inc. | United States |
Foresight Biotherapeutics, Inc. | United States |
Jerini Ophthalmic, Inc** | United States |
JPT
Peptide Technologies Inc | United States |
Knight Newco 1, Inc. | United States |
Laboratorios Baxalta S.A. | United States |
Lotus Tissue Repair Inc | United States |
Lumena Pharmaceuticals LLC | United States |
Meritage Pharma, Inc. | United States |
NPS
Pharma Holdings U.S., Inc. | United States |
NPS Services, L.C. | United States |
Rare Disease Charitable Foundation | United States |
SARcode Bioscience Inc. | United States |
Shire Brandywine LLC | United States |
Shire Development LLC | United States |
Shire
Executive Services LLC | United States |
Shire Holdings US AG | United States |
Shire Human Genetic Therapies Securities Corporation | United States |
Shire Human Genetic Therapies, Inc. | United States |
Shire Incorporated | United States |
Shire Invicta US Inc | United
States |
Shire LLC | United States |
Shire North American Group Inc. | United States |
Shire Orphan Therapies LLC | United States |
Shire Pharmaceutical Development Inc | United States |
Shire Pharmaceuticals LLC | United States |
Shire Properties US | United
States |
Shire Regenerative Medicine LLC* | United States |
Shire Regulatory Inc | United States |
Shire Supplies U.S. LLC | United States |
Shire US Holdings LLC | United States |
Shire US Inc | United States |
Shire US Investment Inc | United
States |
Shire US Manufacturing Inc | United States |
Shire ViroPharma Incorporated | United States |
Shire-NPS Pharmaceuticals, Inc. | United States |
VCO Incorporated | United States |
Viropharma Biologics Inc | United States |
Viropharma Holdings LLC | United
States |
VPDE Incorporated | United States |
VPINT Incorporated | United States |
Shire Pharmaceuticals Investments (British Virgin Islands) Limited | British Virgin Islands |